medRxiv Preprint Server
May 31, 2026
Yves Martins Varela, Patrícia Cavalcanti-Ribeiro, Geovan Menezes de Sousa et al.
preprint
Background Ketamine has emerged as an effective rapid-acting treatment for treatment-resistant depression (TRD), producing significant antidepressant effects within hours of administration. Given ketamine’s capacity to induce states of heightened neuroplasticity and psychological openness, psychotherapy may represent a meaningful complement to its pharmacological effects — facilitating...
npj Mental Health Research
May 30, 2026
Kenni Wojujutari Ajele, Botho Nanvula Ramonkga, Matthew O Olasupo et al.
Anxiety, depression, and stress are common in individuals with diabetes and cancer and are associated with poor self-management and well-being. Cognitive behavioral therapy (CBT) and mindfulness-based interventions (MBIs) are widely used in nonpharmacological treatments, but their comparative effectiveness remains unclear. We conducted a stratified subgroup meta-analysis to indirectly compare...
Journal of Education and Development
May 29, 2026
Michiyo Ando, Hiroko Kukihara, Sayoko Ito
Background: Care wokers experience much stress becase of physical and emotional lavor. They often were hurted. Mindfulness yoga is one of the most useful intervention. Purpose: The purpose of this study was to investigate effects of mindfulness yoga on self-compassion, depression, resilience, and happiness of care workers. Method: Participants were 11 care workers consisting of nurses and...
Journal of Pain & Palliative Care Pharmacotherapy
May 29, 2026
Yogendra Singhal, Pavan Gaurav R, Sreeharsh Saji et al.
Depression is a common and serious concern in cancer patients, significantly impacting quality of life, treatment adherence, and overall prognosis. While traditional antidepressants often take weeks to exert therapeutic effects, ketamine has emerged as a potential alternative due to its rapid antidepressant action. This systematic review explores the efficacy, safety, and clinical role of...
Translational Psychiatry
May 29, 2026
Justyna K. Hinchcliffe, Katie Kamenish, Julia M. Bartlett et al.
Affective biases shape cognitive and emotional behaviour and are important in major depressive disorder (MDD). Modulation of affective biases by the NMDA antagonist, ketamine, may underlie its antidepressant effects but not all NMDA antagonists are efficacious. Some studies suggest ketamine's efficacy involves non-NMDA mechanisms e.g. via its active metabolite HNK (2R, 6R)-hydroxynorketamine),...
Clinical Pharmacology & Therapeutics
May 28, 2026
Gia Han Le, Sabrina Wong, Danica E. Johnson et al.
Major depressive disorder (MDD) and treatment-resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor-level treatment strategies beyond monoamine reuptake. The serotonin 5-HT2B receptor (5-HT2BR) is uniquely positioned at the interface of central-antidepressant mechanisms and peripheral cardiac risks. Herein, we reviewed preclinical, translational and...
May 27, 2026
James Phelps
A new randomized trial found serial intravenous ketamine was not significantly more effective than the active placebo midazolam in reducing depressive symptoms or improving quality of life. While the study may have been underpowered due to a small sample size (n=63), the improvement in MADRS scores fell short of the minimal clinically important difference. The study faced blinding failures,...
Psychotherapy and Psychosomatics
May 27, 2026
Lea J. Mertens, Felix Betzler, Manuela Brand et al.
Psilocybin shows promise for treatment-resistant depression (TRD), but long-term data are limited. This study examined the antidepressant effect of one or two psilocybin doses with adjunct psychotherapy in TRD until twelve months. This is a naturalistic follow-up of a phase 2b, randomized, active placebo-controlled trial, where participants were randomized to receive two drug administrations...
European Journal of Psychotraumatology
May 26, 2026
Xiuchuan He, Yuanli Ren, Qian Bian et al.
Background: Depression and anxiety are common mental health problems that frequently co-occur with trauma-related disorders and often develop following traumatic or stressful events, substantially impairing quality of life. Mindfulness-based interventions have been shown to reduce these symptoms; however, their widespread implementation is often limited by poor accessibility and low adherence....
Expert Opinion on Investigational Drugs
May 26, 2026
Mina Takahashi, Richard C. Shelton
INTRODUCTION: Bipolar depression with acute suicidal ideation and behavior (ASIB) is a life- threatening manifestation of bipolar disorder (BD), with a suicide risk higher than that in other psychiatric disorders and the general population. Rapid and effective interventions are critical, as traditional therapies are often slow and frequently insufficient. Currently, no drug is approved by the...
Australian & New Zealand Journal of Psychiatry
May 26, 2026
Yash Giri, Paul Furst, Colleen Loo et al.
1 citation
Treatment-resistant depression is a condition with significant morbidity, despite the current standard of treatment, including traditional pharmacotherapy, psychotherapy, augmentation strategies and electroconvulsive therapy. While novel therapies have emerged, such as ketamine/esketamine, transcranial magnetic stimulation and psilocybin-assisted therapy, the uptake of these treatments is...
Journal of Nursing Education and Practice
May 25, 2026
Albany LaGore, Nadine Kridli, Ron Piscotty et al.
Background: Adolescents with neurological disorders (NDs) experience significantly higher rates of depression, anxiety, or both relative to adolescents in the general population. The purpose of this systematic narrative review was to examine the existing literature evaluating the effects of mindfulness-based interventions (MBIs) on anxiety, depression, or both among adolescents with a known ND....
Biomedicines
May 23, 2026
Dominik Jucha, Michał Klimas, Dominika Wiśniewska et al.
Background/Objectives: Bipolar disorder affects about 40 million people worldwide, and the greatest burden of the disease is associated with depressive episodes. About 25% of patients experience drug-resistant depression, in which standard treatment turns out to be insufficient, and monotherapy often does not bring full remission. Despite the use of second-generation antipsychotics, the...
Psychopharmacology
May 22, 2026
Wei-Chen Lin, Li-Kai Cheng, Tung-Ping Su et al.
Background: Studies have demonstrated that subanesthetic-dose ketamine may modulate the functioning of specific depression-related brain regions, particularly the anterior cingulate cortex and prefrontal cortex. However, how subanesthetic-dose ketamine alters the global and regional graph theory metrics of resting-state functional connectivity in patients with treatment-resistant depression...
Therapeutic Advances in Psychopharmacology
May 22, 2026
Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort et al.
Background: Ketamine and esketamine ((es)ketamine) rapidly reduce depressive symptoms and suicidal ideation (SI) in treatment-resistant depression (TRD), but whether early SI improvement during the acute phase of the treatment predicts reduced suicide-associated emergency department (SAED) visits over the longer term remains unclear. Objectives: To examine whether early improvements in SI,...
Current Topics in Medicinal Chemistry
May 21, 2026
Guizhen Lyu, Dongbing Li
Depression is a leading cause of global disability, affecting over 300 million individuals and imposing substantial personal, clinical, and societal burdens. This comprehensive review synthesizes recent advances in understanding depression across biological, cognitive, and psychosocial domains, emphasizing innovations in diagnosis, pathophysiology, and treatment. We explore emerging...
Scientific Reports
May 20, 2026
Guan-Jie She, Wei-Chi Li, Chun-Hsiang Chou et al.
Emerging evidence shows that ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, can produce rapid anti-suicidal effects in treatment-resistant depression, yet its underlying neuropharmacological mechanisms remain elusive. The present study aimed at investigating the therapeutic effect of ketamine infusion on suicidal ideation by examining hemodynamic response changes in resting-state...
Pharmacological Reports
May 20, 2026
Aleksander Kwaśny, Alina Wilkowska, Michał Pastuszak et al.
Background: Treatment-resistant depression (TRD) poses a significant therapeutic challenge, with remission often unattainable. Recognition and detection of treatment-emergent adverse events (TEAEs) are essential, as these events may significantly influence the quality of treatment response. This knowledge aids in personalizing care and selecting the best treatment strategy. Methods: In a...
Frontiers in Pharmacology
May 19, 2026
Fernanda Pilatti, Marieli Philippsen, A. G. Bertollo et al.
Major Depressive Disorder (MDD) is a highly prevalent and disabling psychiatric disorder, representing a major global health burden across all age groups. Increasing evidence indicates that its pathophysiology involves a complex interplay between chronic stress, dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, immune activation, and neuroinflammation. Persistent HPA axis...
Therapeutic Advances in Psychopharmacology
May 19, 2026
correction
[This corrects the article DOI: 10.1177/20451253261437597.].